(EMAILWIRE.COM, March 30, 2019 ) According to new market research report the competent cells market is projected to reach USD 2.22 Billion by 2022 from an estimated USD 1.37 Billion in 2017, at a CAGR of 10.2%. The growth of this market is attributed to factors such as advancements in molecular cloning research due to the emergence of new technologies and the growing commercial demand for molecular cloned products and recombinant proteins.
Product launches, acquisitions, and partnerships were some of the major strategies followed by key players in the competent cells market. These strategies were adopted by-Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), New England Biolabs (U.S.), GenScript Biotech Corporation (China), and Agilent Technologies, Inc. (U.S.).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=265815900
Thermo Fisher Scientific, Inc. is one of the key players in the competent cells market. The company focuses on product launches, acquisitions, and agreements to enhance its presence in the market. In January 2016, Thermo Fisher acquired Affymetrix (U.S.), to strengthen its leadership in biosciences and to create new market opportunities in genetic analysis. Similarly, in February 2014, the company acquired Life Technologies Inc. (U.S.). After this acquisition, Thermo Fisher created a new business segment-Life Sciences Solutions- which includes a broad range of protein expression systems and their related products.
Sample of the report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=265815900
Merck KGaA accounted for the second largest share of the competent cells market in 2016. The company focuses on acquisitions and partnerships to maintain its leading position in the market. In November 2015, Merck KGaA acquired Sigma-Aldrich Co., LLC. (U.S.), an established player in the life science industry. Sigma-Aldrich offers a broad range of protein expression products. This acquisition will increase the dominance of Merck KGaA in the competent cells market. In 2015, Merck KGaA and Celares GmbH (Germany) collaborated to provide pegylation services to customers developing protein-based therapeutics and biosimilars.
New England Biolabs, Inc. commanded for the third-largest share of the global competent cells market in 2016. The company offers restriction endonucleases, DNA modifying enzymes, library preparation for next-generation sequencing, nucleic acid purification, competent cells, markers and ladders, RNA reagents, gene expression, cellular analysis, epigenetics, and protein expression & purification technologies. New England Biolabs operates in North America, Europe, and Asia-Pacific. The company focuses on product launches, acquisitions, and agreements to enhance its presence in the competent cells market.

Know more: https://www.marketsandmarkets.com/Market-Reports/competent-cells-market-265815900.html